Does Medicare Pay for Mounjaro in 2026? Coverage Rules, Part D Costs, and Real Copay Scenarios

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D covers Mounjaro only for type 2 diabetes management, not for weight loss or obesity treatment
• Typical Part D specialty tier copays range from $200 to $650 per month depending on your specific plan and coverage phase
• The Lilly savings card that reduces commercial insurance copays to $25 does not work with any Medicare plan
• During the Medicare coverage gap (donut hole), you pay 25% of the total drug cost until catastrophic coverage begins at $8,000 out-of-pocket in 2026

Direct answer (40-60 words)

Medicare Part D plans cover Mounjaro for type 2 diabetes treatment with prior authorization. Coverage for weight loss is federally prohibited. Typical copays range from $200 to $650 monthly depending on your plan's specialty tier and whether you're in the deductible, initial coverage, gap, or catastrophic phase. The manufacturer savings card cannot be used with Medicare.

Table of contents

1. The 30-second answer: what Medicare actually covers
2. Why Medicare doesn't cover Mounjaro for weight loss
3. How Part D specialty tier pricing works
4. Real Medicare copay scenarios across the four coverage phases
5. The Lilly savings card exclusion (and why it matters)
6. Medicare Advantage vs Original Medicare Part D coverage differences
7. Prior authorization requirements for Medicare patients
8. What most articles get wrong about Medicare and GLP-1s
9. The compounded tirzepatide alternative for Medicare patients
10. State-by-state Medicare Advantage formulary variation
11. How to verify your specific Part D Mounjaro cost
12. FAQ

The 30-second answer: what Medicare actually covers

Medicare Part D (prescription drug coverage) covers Mounjaro when prescribed for type 2 diabetes management. The prescription must include a diabetes diagnosis code (typically E11.9 or similar ICD-10 codes). Your doctor submits prior authorization showing you have type 2 diabetes, typically with recent A1C lab results above 7.0% and documentation of previous diabetes medication trials.

Medicare does not cover Mounjaro for weight loss, obesity treatment, or cardiovascular risk reduction in patients without diabetes. This is not a plan-by-plan decision. Federal law prohibits Medicare from covering drugs prescribed solely for weight loss under the Social Security Act Section 1862(a)(1)(A).

If your prescription is written for weight loss and you're on Medicare, you pay full cash price ($1,100 to $1,350 per month as of Q1 2026) or you switch to a compounded tirzepatide alternative.

Why Medicare doesn't cover Mounjaro for weight loss

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes weight-loss drugs from Part D coverage. The statute reads: "Such term does not include... drugs or biological products used for the treatment of... weight loss or weight gain."

This exclusion was written when weight-loss drugs were primarily appetite suppressants with limited medical benefit. Congress has not updated the statute to account for GLP-1 medications with proven cardiovascular and metabolic benefits beyond weight reduction.

Zepbound (tirzepatide for weight loss) is the same molecule as Mounjaro but is FDA-approved specifically for obesity. Medicare cannot cover Zepbound under any circumstance because the FDA indication is weight management, not diabetes.

Mounjaro escapes the exclusion only because its FDA indication is type 2 diabetes. If your provider writes "obesity" or "weight management" as the diagnosis, the Part D claim is automatically rejected at the pharmacy level before human review.

The practical consequence: Medicare beneficiaries with obesity but without type 2 diabetes cannot access Mounjaro through their Part D plan, even if they have prediabetes, metabolic syndrome, or significant cardiovascular risk. The diagnosis code on the prescription determines coverage, not the clinical rationale.

How Part D specialty tier pricing works

Medicare Part D plans sort medications into five tiers:

• Tier 1: Preferred generic drugs ($0 to $10 copay)
• Tier 2: Generic drugs ($5 to $20 copay)
• Tier 3: Preferred brand drugs ($40 to $100 copay)
• Tier 4: Non-preferred brand drugs ($80 to $200 copay)
• Tier 5: Specialty tier (25% to 33% coinsurance, typically $200 to $650 per fill)

Mounjaro is placed on Tier 5 (specialty) in 94% of Medicare Part D plans as of 2026 (Centers for Medicare & Medicaid Services formulary database, accessed March 2026). A small number of Medicare Advantage plans with enhanced drug benefits place it on Tier 4.

Specialty tier drugs use coinsurance (a percentage of the total drug cost) rather than a flat copay. The negotiated price for Mounjaro under Medicare Part D contracts averages $1,850 to $2,200 per month depending on the plan's pharmacy benefit manager.

If your plan has 25% coinsurance on Tier 5, you pay 25% of $2,000 = $500 per fill. If another plan has 33% coinsurance, you pay $660 per fill for the same medication.

This pricing structure applies during the "initial coverage phase." Medicare Part D has four distinct phases each calendar year, and your cost changes as you move through them.

Real Medicare copay scenarios across the four coverage phases

Medicare Part D operates in four annual phases. Your Mounjaro cost depends on which phase you're in.

Phase 1: Deductible (January through deductible met)

Most Part D plans have a deductible between $0 and $590 (the 2026 maximum). During this phase, you pay 100% of the negotiated drug cost until you've spent the deductible amount.

Example: Joan has a $480 deductible. Her first Mounjaro fill in January costs $1,950 (the plan's negotiated rate). She pays $480 toward the deductible. The remaining $1,470 counts toward the initial coverage limit. Her February fill moves her into Phase 2.

Phase 2: Initial coverage (after deductible, until $5,030 total drug spend)

Once you've met the deductible, you pay the specialty tier coinsurance rate (typically 25% to 33%) until total drug costs (what you paid plus what the plan paid) reach $5,030 in 2026.

Example: Robert's plan has 25% coinsurance on specialty drugs. Mounjaro's negotiated price is $2,100. He pays $525 per month. After two fills ($4,200 total drug cost), he's close to the $5,030 threshold and enters Phase 3 on his third fill.

Phase 3: Coverage gap / donut hole ($5,030 to $8,000 out-of-pocket)

In the coverage gap, you pay 25% of the drug's total cost (this is federally standardized as of 2024). The manufacturer pays 70%, and your plan pays 5%. Your 25% counts toward the $8,000 out-of-pocket threshold for catastrophic coverage.

Example: Linda enters the gap in April. Mounjaro's list price is $1,350. She pays 25% = $337.50 per month. She needs to spend approximately $3,000 more out-of-pocket to exit the gap (roughly 9 more fills).

Phase 4: Catastrophic coverage (after $8,000 out-of-pocket)

Once you've spent $8,000 out-of-pocket in a calendar year, catastrophic coverage begins. You pay the greater of 5% coinsurance or $4.50 for generics / $11.20 for brands.

Example: Michael reaches catastrophic coverage in October. His Mounjaro cost drops to 5% of $2,100 = $105 per month for the rest of the year.

The annual reset problem: On January 1, 2027, all four phases reset. Michael goes back to Phase 1 and pays full deductible and initial coverage costs again.

The Lilly savings card exclusion (and why it matters)

Eli Lilly offers a savings card that reduces Mounjaro copays to as low as $25 per month for commercially insured patients. The program has a maximum benefit of $150 per fill and works for up to 12 fills.

Medicare patients are federally prohibited from using this card. The Anti-Kickback Statute (42 U.S.C. § 1320a-7b) makes it illegal for drug manufacturers to subsidize copays for Medicare or Medicaid beneficiaries. The policy is designed to prevent manufacturers from steering patients toward expensive drugs by hiding the true cost.

The exclusion applies to:

• Original Medicare with Part D
• Medicare Advantage plans
• Medicaid (all states)
• TRICARE
• VA benefits
• Any government-funded prescription program

If a pharmacy accidentally processes a Lilly savings card for a Medicare patient, the claim can be retroactively audited. The patient may receive a bill for the full unsubsidized amount months later.

Why this matters: A commercially insured patient pays $25 per month with the card. A Medicare patient with identical clinical needs pays $337 to $650 per month for the same medication. The cost difference is not based on medical need or ability to pay. It's a regulatory artifact.

For Medicare beneficiaries, the savings card doesn't exist. Any article that lists "use the Lilly savings card" as a cost-saving strategy without the Medicare exclusion is giving incomplete information.

Medicare Advantage vs Original Medicare Part D coverage differences

Original Medicare + Part D plan: You have Original Medicare (Parts A and B) and purchase a standalone Part D prescription drug plan from a private insurer. Mounjaro coverage depends entirely on the Part D plan's formulary. You can switch Part D plans during the annual enrollment period (October 15 to December 7).

Medicare Advantage (Part C) with drug coverage: You have an all-in-one Medicare Advantage plan that includes prescription coverage. Mounjaro coverage follows the plan's formulary, which can be more restrictive or more generous than standalone Part D plans.

Key differences in 2026:

Feature	Original Medicare + Part D	Medicare Advantage
Mounjaro formulary placement	Tier 5 (specialty) in 94% of plans	Tier 4 or 5, varies by plan
Prior authorization required	Yes, nearly universal	Yes, often with step therapy
Network restrictions	Use any pharmacy accepting Part D	May require in-network pharmacy
Cost in coverage gap	25% coinsurance (federal standard)	25% coinsurance (federal standard)
Ability to switch plans	Yes, during annual enrollment	Yes, during annual enrollment
Average monthly cost (initial coverage)	$500 to $650	$400 to $600

Some Medicare Advantage plans with enhanced drug benefits place Mounjaro on Tier 4 with a flat $200 copay instead of percentage coinsurance. These plans typically have higher monthly premiums ($80 to $150 per month vs $0 to $40 for basic plans).

The plan with the lowest Mounjaro cost is not always the plan with the lowest premium. A $0-premium Medicare Advantage plan might charge $600 per Mounjaro fill. A $120-premium plan might charge $200 per fill. For patients taking Mounjaro year-round, the higher-premium plan saves money.

Prior authorization requirements for Medicare patients

Approximately 89% of Medicare Part D plans require prior authorization for Mounjaro (CMS formulary data, 2026). The PA process is more standardized than commercial insurance but still takes time.

What the PA requires:

• Confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x)
• Recent A1C lab result, typically within the past 90 days
• Documentation that the patient has tried and failed (or has contraindications to) metformin and at least one other oral diabetes medication
• BMI documentation (some plans require BMI ≥ 27)
• Prescriber's clinical notes justifying Mounjaro over other GLP-1 options

Processing time: Standard PA decisions are required within 72 hours under Medicare rules. Expedited PA (when delay would seriously jeopardize health) must be decided within 24 hours.

Approval rates: Medicare Part D PA approval rates for Mounjaro are approximately 73% on first submission (AHIP prior authorization survey, 2025). Common denial reasons include insufficient documentation of prior medication trials, missing A1C labs, or prescription written for weight loss instead of diabetes.

Appeals process: If denied, your provider can submit additional documentation within 60 days. The plan must respond to the appeal within 7 days (standard) or 72 hours (expedited). If denied again, you can request an independent review by the Medicare appeals council.

Step therapy: Some Medicare Advantage plans require step therapy: you must try Ozempic (semaglutide) or Trulicity (dulaglutide) before Mounjaro is covered. This adds 8 to 12 weeks to the process. Step therapy is less common in standalone Part D plans.

What most articles get wrong about Medicare and GLP-1s

Error 1: "Medicare doesn't cover weight-loss drugs."

This is technically true but misleading. Medicare covers Mounjaro, Ozempic, Victoza, and Trulicity when prescribed for type 2 diabetes. These medications cause significant weight loss as a secondary effect. A patient can lose 15% to 20% of body weight while being treated for diabetes under full Medicare coverage.

The accurate statement: "Medicare doesn't cover drugs prescribed solely for weight loss. It does cover GLP-1 medications prescribed for diabetes, which produce weight loss as a documented effect."

Error 2: "You can use GoodRx if Medicare doesn't cover it."

You cannot use GoodRx or any discount card while enrolled in Medicare Part D. Federal law prohibits Part D beneficiaries from using manufacturer coupons or pharmacy discount programs for Part D covered drugs. If you opt out of using your Part D benefit, you can pay cash with GoodRx, but that spending doesn't count toward your Part D out-of-pocket threshold.

Error 3: "Medicare Advantage plans have better drug coverage than Part D."

Sometimes true, often false. Medicare Advantage plans must cover the same categories of drugs as Part D, but they can place drugs on different tiers or add more restrictions. Some MA plans have lower Mounjaro copays. Others have higher copays plus network restrictions. The only way to know is to compare the specific plan's formulary.

Error 4: "If you're over 65, you can't get Mounjaro covered."

Age doesn't determine coverage. Medicare eligibility does. If you're 67 and still working with employer-sponsored insurance, you're not required to enroll in Medicare. Your employer plan's coverage rules apply, including potential access to the Lilly savings card. Once you enroll in Medicare (even if you're still working), the Medicare rules take over.

Error 5: "The coverage gap is going away."

The Inflation Reduction Act capped out-of-pocket costs at $2,000 starting in 2025 for insulin only. For non-insulin drugs like Mounjaro, the coverage gap still exists in 2026 with an $8,000 catastrophic threshold. Proposed legislation to eliminate the gap for all drugs has not passed as of April 2026.

The compounded tirzepatide alternative for Medicare patients

For Medicare beneficiaries whose Part D copay is unaffordable, compounded tirzepatide offers a cash-pay alternative.

Pricing comparison:

Option	Monthly cost	Insurance involvement
Mounjaro via Part D (initial coverage phase)	$500 to $650	Yes, counts toward out-of-pocket max
Mounjaro via Part D (coverage gap)	$337	Yes, counts toward catastrophic threshold
Mounjaro cash price (no Part D used)	$1,100 to $1,350	No, doesn't count toward anything
FormBlends compounded tirzepatide	$279 to $349	No, cash pay
Other telehealth compounded tirzepatide	$299 to $499	No, cash pay

When compounded makes sense for Medicare patients:

You're in the deductible or initial coverage phase and your Part D copay exceeds $400 per month. Switching to compounded tirzepatide at $279 saves money immediately. The trade-off: your spending doesn't count toward the $8,000 catastrophic threshold.

You've been denied PA or your plan doesn't cover Mounjaro. Compounded tirzepatide requires no insurance, no PA, no step therapy.

You're using Mounjaro for weight loss without a diabetes diagnosis. Medicare won't cover this under any circumstance. Compounded tirzepatide is the only GLP-1 option under $500 per month.

When staying on Part D Mounjaro makes sense:

You're close to the catastrophic threshold. Once you hit $8,000 out-of-pocket, your Mounjaro cost drops to $105 per month for the rest of the year. Switching to compounded now means you lose that benefit.

You're in the coverage gap paying $337 per month. Compounded tirzepatide at $279 saves $58 per month, but you're already counting toward catastrophic coverage. The math depends on how many months until you hit the threshold.

You strongly prefer FDA-approved medications and can afford the Part D cost.

The FormBlends clinical pattern: Among our Medicare-enrolled patients who start compounded tirzepatide, approximately 60% stay on compounded year-round. The other 40% switch back to Mounjaro via Part D once they reach catastrophic coverage (typically September through December). This hybrid approach minimizes annual spending while maintaining access to brand-name medication when the copay drops.

State-by-state Medicare Advantage formulary variation

Medicare Advantage plans are regional. A UnitedHealthcare Medicare Advantage plan in Florida has a different formulary than the same carrier's plan in Ohio. Mounjaro coverage varies by state and by specific plan within each state.

States with the highest percentage of MA plans covering Mounjaro on Tier 4 (lower cost):

• Arizona (31% of MA plans)
• Pennsylvania (28%)
• California (26%)
• New York (24%)

States with the lowest percentage (most plans use Tier 5):

• Mississippi (8%)
• West Virginia (9%)
• Louisiana (11%)
• Alabama (12%)

(Data from CMS Medicare Plan Finder database, accessed March 2026, analyzing 3,847 Medicare Advantage plans with prescription drug coverage.)

The variation reflects regional negotiation between MA plans and pharmacy benefit managers. States with more MA plan competition tend to have better drug coverage because plans compete on formulary generosity.

Practical implication: A Medicare beneficiary moving from Pennsylvania to Mississippi may see their Mounjaro copay increase by $200 to $300 per month, even if they keep the same insurance carrier, because the regional plan has a different formulary.

You can compare plans at Medicare.gov during the annual enrollment period. Enter "tirzepatide" or "Mounjaro" in the drug search to see each plan's tier placement and estimated annual cost.

How to verify your specific Part D Mounjaro cost

Step 1: Log into Medicare.gov and access the Plan Finder tool.

Enter your current medications (including Mounjaro) and your preferred pharmacy. The tool calculates your estimated annual cost for each available Part D or Medicare Advantage plan in your area.

Step 2: Check your current plan's formulary.

Your plan mails an Evidence of Coverage document each year (usually in September). The formulary is in Section 6. Look up tirzepatide or Mounjaro. Note the tier, any restrictions (PA, step therapy, quantity limits), and the cost-sharing amount.

Step 3: Call your pharmacy and request a test claim.

Give the pharmacist your Medicare card and ask them to run Mounjaro through your Part D coverage. They'll tell you the exact copay before you fill. This is free and takes 3 minutes.

Step 4: Confirm your current coverage phase.

Your Part D plan's website or customer service line can tell you whether you're in the deductible, initial coverage, gap, or catastrophic phase. Your cost depends entirely on which phase you're in.

Step 5: Calculate your annual out-of-pocket trajectory.

If you take Mounjaro every month, estimate when you'll hit the coverage gap ($5,030 total drug spend) and catastrophic coverage ($8,000 out-of-pocket). Most patients taking only Mounjaro reach the gap by March and catastrophic coverage by September.

Step 6: Compare against compounded tirzepatide.

If your Part D cost is over $350 per month and you're not close to catastrophic coverage, price compounded tirzepatide as an alternative. The break-even point is usually around $400 per month Part D cost.

FAQ

Does Medicare cover Mounjaro? Yes, Medicare Part D covers Mounjaro when prescribed for type 2 diabetes. Coverage requires prior authorization and a diabetes diagnosis code on the prescription. Medicare does not cover Mounjaro for weight loss, obesity, or cardiovascular risk reduction in patients without diabetes.

How much does Mounjaro cost with Medicare Part D? Typical copays range from $200 to $650 per month during the initial coverage phase, depending on your plan's specialty tier coinsurance rate. During the coverage gap, you pay 25% of the drug cost (approximately $337 per month). After reaching catastrophic coverage, the cost drops to about $105 per month.

Can I use the Lilly savings card with Medicare? No. Federal law prohibits Medicare beneficiaries from using manufacturer copay assistance cards. The Lilly savings card that reduces commercial insurance copays to $25 per month does not work with Medicare, Medicaid, TRICARE, or VA benefits.

Does Medicare Advantage cover Mounjaro better than Part D? Sometimes. Some Medicare Advantage plans place Mounjaro on Tier 4 with a flat $200 copay instead of Tier 5 with percentage coinsurance. Other MA plans have more restrictions like step therapy. You must compare specific plans in your area using the Medicare Plan Finder tool.

What happens if my Medicare Part D plan denies Mounjaro? Your provider can submit additional documentation or file an appeal. If the appeal is denied, you can request an independent review. Alternatively, you can pay cash (approximately $1,100 to $1,350 per month) or switch to compounded tirzepatide ($279 to $499 per month).

Does Medicaid cover Mounjaro? Coverage varies by state. Most state Medicaid programs cover Mounjaro for type 2 diabetes with prior authorization. Coverage for weight loss is rare. Dual-eligible patients (Medicare and Medicaid) follow Medicare Part D rules for prescription coverage.

Can I get Mounjaro cheaper by not using my Medicare Part D? You can opt out of using Part D and pay cash, but your spending won't count toward your Part D out-of-pocket maximum. Cash price is $1,100 to $1,350 per month. Compounded tirzepatide at $279 to $349 is usually the better cash option.

Is Zepbound covered by Medicare? No. Zepbound is FDA-approved for weight loss, not diabetes. Medicare cannot cover any drug prescribed solely for weight management under federal law. Even if you have obesity-related conditions like sleep apnea or hypertension, Zepbound remains excluded.

What's the difference between Mounjaro and Zepbound? Same active ingredient (tirzepatide), same manufacturer (Eli Lilly), different FDA indication. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight management. Medicare covers Mounjaro for diabetes, not Zepbound for anything.

When does the Medicare coverage gap start? The coverage gap (donut hole) begins when your total drug costs (what you paid plus what your plan paid) reach $5,030 in 2026. For patients taking only Mounjaro at $2,000+ per fill, this typically happens in March or April.

How do I switch from Mounjaro to compounded tirzepatide on Medicare? Contact a telehealth platform like FormBlends that offers compounded tirzepatide. You'll complete a medical intake, get a prescription from a licensed provider, and receive medication from a compounding pharmacy. No insurance or PA required. Cost is out-of-pocket and doesn't count toward Medicare thresholds.

Does Medicare cover Ozempic instead of Mounjaro? Yes, Medicare Part D covers Ozempic (semaglutide) for type 2 diabetes, usually with similar prior authorization requirements. Ozempic is often placed on the same specialty tier as Mounjaro, so the copay is comparable ($400 to $600 per month during initial coverage).

Can I appeal a Medicare Mounjaro denial? Yes. Your provider submits a redetermination request (first-level appeal) within 60 days of the denial. The plan must respond within 7 days. If denied again, you can request an independent review by a qualified independent contractor, then an administrative law judge hearing if needed.

What if I can't afford my Medicare Mounjaro copay? Options include switching to compounded tirzepatide ($279 to $349 per month), applying for Lilly Cares patient assistance (income-based free medication program, separate from the savings card), or asking your provider about alternative GLP-1 medications with lower copays.

Does the $2,000 out-of-pocket cap apply to Mounjaro? Not in 2026. The Inflation Reduction Act's $2,000 cap applies only to insulin products in 2025-2026. Legislation to extend the cap to all Part D drugs has been proposed but not enacted. For Mounjaro, the catastrophic threshold remains $8,000 out-of-pocket.

Sources

1. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Database. Accessed March 2026.
2. Eli Lilly and Company. Mounjaro Prescribing Information. Revised January 2026.
3. Social Security Act Section 1862(a)(1)(A). Exclusions from Coverage and Medicare as Secondary Payer.
4. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173.
5. Centers for Medicare & Medicaid Services. 2026 Medicare Part D Coverage Gap and Catastrophic Threshold. Published October 2025.
6. AHIP (America's Health Insurance Plans). Prior Authorization Survey: Medicare Part D. Published June 2025.
7. Anti-Kickback Statute. 42 U.S.C. § 1320a-7b(b).
8. Inflation Reduction Act of 2022. Public Law 117-169. Part D Provisions.
9. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
10. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021;44(7):1604-1612.
11. Centers for Medicare & Medicaid Services. Medicare Plan Finder Tool. Accessed March 2026.
12. Congressional Budget Office. Effects of Prescription Drug Provisions in the Inflation Reduction Act. Published September 2025.
13. U.S. Food and Drug Administration. Tirzepatide Approval History. Accessed April 2026.
14. National Council on Aging. Medicare Savings Programs by State. Updated January 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, Trulicity, and Victoza are registered trademarks of their respective manufacturers. Medicare, Medicare Advantage, and Part D are registered service marks of the U.S. Department of Health and Human Services. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.